Levin Capital Strategies L.P. Increases Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Levin Capital Strategies L.P. raised its position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 440.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 54,000 shares of the company’s stock after buying an additional 44,000 shares during the period. Levin Capital Strategies L.P.’s holdings in EyePoint Pharmaceuticals were worth $402,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Bank of New York Mellon Corp boosted its position in EyePoint Pharmaceuticals by 22.2% during the 4th quarter. Bank of New York Mellon Corp now owns 204,260 shares of the company’s stock valued at $1,522,000 after buying an additional 37,054 shares during the period. Rhumbline Advisers boosted its position in EyePoint Pharmaceuticals by 16.1% during the 4th quarter. Rhumbline Advisers now owns 89,560 shares of the company’s stock valued at $667,000 after buying an additional 12,443 shares during the period. Deltec Asset Management LLC purchased a new stake in EyePoint Pharmaceuticals during the 4th quarter valued at $151,000. abrdn plc purchased a new stake in shares of EyePoint Pharmaceuticals in the 4th quarter worth about $1,719,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of EyePoint Pharmaceuticals by 40.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,472 shares of the company’s stock worth $108,000 after purchasing an additional 4,179 shares during the period. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Citigroup assumed coverage on shares of EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating and a $33.00 target price for the company. Robert W. Baird dropped their target price on shares of EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating for the company in a research report on Monday, November 11th. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 target price on shares of EyePoint Pharmaceuticals in a research report on Thursday, December 5th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $33.00 target price on shares of EyePoint Pharmaceuticals in a research report on Thursday, February 6th. One analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $26.63.

EyePoint Pharmaceuticals Price Performance

Shares of NASDAQ EYPT opened at $6.27 on Friday. EyePoint Pharmaceuticals, Inc. has a 1 year low of $5.78 and a 1 year high of $28.79. The stock has a market cap of $427.93 million, a P/E ratio of -3.14 and a beta of 1.51. The firm has a 50-day moving average of $7.34 and a 200 day moving average of $8.51.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.